3 results
The primary objective is to demonstrate the superiority of ziltivekimab 15 mg s.c. once-monthly in reducing the risk of MACE (as defined by the primary endpoint) compared to placebo, both added to standard of care, in participants with established…
The objective of the study is to develop and test a blended vision-specific E-health-based cognitive behavioral & self-management intervention (*E-nergEYEze*). Our specific goals are: (1) to further develop E-nergEYEze for visually impaired…
Primary Objective:To evaluate the efficacy of taldefgrobep alfa in participants who are already taking a stable dose of nusinersen or risdiplam or have a history of onasemnogene abeparvovec-xioi, compared to placebo, measured by change in the 32…